RYTM — Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Q2 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Global Net Product Sales: $71.3 million, a 19% sequential increase from Q1 2026 ($60.1 million).
• U.S. Revenue: $51 million (72% of total revenue), driven by the launch of IMCIVREE for acquired hypothalamic obesity (HO).
• International Revenue: Decreased from $23.2 million to $20.3 million, primarily due to a $3.8 million retrospective charge in France.
• R&D Expenses: $43.4 million, up from $42.3 million year-over-year, driven by increased spending on clinical trials.
• SG&A Expenses: $67.4 million, up from $45.9 million year-over-year, attributed to higher personnel costs.
• GAAP EPS: Net loss of $0.73 per share.
• Cash Position: Approximately $331 million, expected to fund operations for at least 24 months.

2. Strategic Updates and Business Highlights

• IMCIVREE Launch: Strong start with over 400 start forms received from approximately 300 prescribers in the first 14 weeks post-approval.
• Clinical Data: Positive results from RM-718's Phase II trial in acquired HO, showing comparable efficacy to setmelanotide with a favorable tolerability profile.
• Market Opportunities: Estimated 10,000 patients in the U.S. with acquired HO, with similar numbers in Europe and Japan.
• International Expansion: Anticipated approval and launch of IMCIVREE in Japan by year-end 2026, with ongoing efforts for market access in Europe.

3. Forward Guidance and Outlook

• Operating Expenses: Updated guidance for 2026 non-GAAP operating expenses to $363 million to $397 million.
• R&D Guidance: Non-GAAP R&D expenses expected to be $175 million to $195 million, with a $20 million reduction in the midpoint due to timing shifts in clinical activities.
• Launch Expectations: Continued growth anticipated in the U.S. for acquired HO and BBS, with a focus on expanding prescriber engagement and patient identification.

4. Challenges and Points of Concern

• International Revenue Decline: The decrease in international revenue due to the retrospective charge raises concerns about market dynamics in Europe.
• Discontinuation Rates: Uncertainty around future discontinuation rates for IMCIVREE in the HO population, although initial metrics are encouraging.
• Competitive Landscape: Potential competition from GLP-1 medications, although no step edits have been noted by payers for IMCIVREE.
• Regulatory Risks: Ongoing regulatory processes in Japan and Europe could impact timelines for market access.

5. Notable Q&A Insights

• Discontinuation Rates: Management indicated that the discontinuation rate for HO patients might be lower than the 30% seen in BBS, but it will be closely monitored.
• Sustainability of Launch Metrics: Questions about the sustainability of patient start forms indicated that while early metrics are strong, the pace may vary due to factors like physician engagement and patient diagnosis.
• Payer Dynamics: Positive early payer experiences noted, with no current step edits for GLP-1s required before IMCIVREE.
• Market Segmentation in PWS: Management emphasized a focus on hyperphagia in Prader-Willi syndrome, acknowledging the complexity and heterogeneity of the disease.

Overall, Rhythm Pharmaceuticals reported a strong quarter with promising early results from the IMCIVREE launch and RM-718 trials, while also navigating challenges in international markets and potential competition. The company remains optimistic about future growth and strategic initiatives.